Sirona Biochem's Anti-Aging Glycoprotein Successfully Extends Cell Life in Serum Deprivation Study
May 20 2014 - 7:45AM
Marketwired
Sirona Biochem's Anti-Aging Glycoprotein Successfully Extends Cell
Life in Serum Deprivation Study
VANCOUVER, BC--(Marketwired
- May 20, 2014) - Sirona Biochem Corp. (TSX-VENTURE: SBM) (OTCQX: SRBCF) (FRANKFURT: ZSB) announces its anti-aging
compound TFC-837 was proven to extend cell life with outstanding
results in a 12-day serum-deprivation study. The study subjected
unprotected and glycoprotein-protected fibroblast cells to a
serum-deprived environment for a period of twelve days. By day ten
of the study, 100% of the unprotected cells were dead. In contrast,
75% of the glycoprotein-protected cells continued to be fully
viable at the conclusion of the twelve day study.
"We couldn't be more excited by these results and the potential
value these compounds can create," commented Mr. Neil Belenkie, CEO
of Sirona Biochem. "Results such as these are the reason we have
attracted globally respected partners for this project, including
Jean-Michel Cousteau, Fabien Cousteau and the Cincinnati Children's
Hospital Medical Center. This is absolutely groundbreaking
technology; the first in a new family of synthetic glycoproteins
successfully created and patented by our scientific team."
Next steps for the development of this compound include
additional studies to validate other cell preservation qualities
and the standard cohort of cosmetic safety studies necessary for
launch of this compound as an anti-aging ingredient. The goal for
this compound is to be available for acquisition by a global
partner within six months. Desired terms for an exclusive license
will be the same as the terms secured in the global exclusive
license with Obagi Medical Products (subsidiary of Valeant
Pharmaceuticals); licensing fee, milestone fee, and an ongoing
royalty payment structure with minimum sales revenue
requirements.
Targeted Applications for this New Family of Compounds
Early data supports targeted applications including the
following:
- Cosmetic (no FDA approval required, inexpensive studies, quick
to market)
- Anti-aging cream (global marketplace, $300 billion in annual
sales)
- Pharmaceutical
- Extend platelet storage beyond current 4-5 day limitation
- Improve outcomes for beta-islet cell transplants
- Improve stem cell storage solution versus conventional
mediums
- Improve organ transplantation donor-to-recipient windows
- Protect against harmful UV or radiation
Project Background
In 1969, an antifreeze glycoprotein was discovered in fish
living under the Antarctic icecaps. The discovery was
groundbreaking because this specific glycoprotein enabled the
Antarctic fish to survive (and not freeze solid) in the subzero
temperatures.
Sirona Biochem's subsidiary, TFChem (France) has synthesized and
stabilized its derivative of this antifreeze glycoprotein for human
use; in the process greatly expanding the protective abilities of
the original antifreeze glycoprotein. While the natural
glycoprotein only protects cells from low temperatures, Sirona
Biochem's patented family of glycoproteins is being tested in
multiple cells types to protect against additional stressed
environments including oxidative stress, UV rays, cold temperatures
and nutrient deprivation.
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery
company with a proprietary platform technology. Sirona specializes
in stabilizing carbohydrate molecules with the goal of improving
efficacy and safety. New compounds are patented for maximum revenue
potential.
Sirona's compounds are licensed to leading companies around the
world in return for licensing fees, milestone fees and ongoing
royalty payments. Sirona's laboratory, TFChem, is located in France
and is the recipient of multiple French national scientific awards
and European Union and French government grants. For more
information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Sirona Biochem cautions you that statements included in this
press release that are not a description of historical facts may be
forward-looking statements. Forward-looking statements are only
predictions based upon current expectations and involve known and
unknown risks and uncertainties. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of release of the relevant information, unless
explicitly stated otherwise. Actual results, performance or
achievement could differ materially from those expressed in, or
implied by, Sirona Biochem's forward-looking statements due to the
risks and uncertainties inherent in Sirona Biochem's business
including, without limitation, statements about: the progress and
timing of its clinical trials; difficulties or delays in
development, testing, obtaining regulatory approval, producing and
marketing its products; unexpected adverse side effects or
inadequate therapeutic efficacy of its products that could delay or
prevent product development or commercialization; the scope and
validity of patent protection for its products; competition from
other pharmaceutical or biotechnology companies; and its ability to
obtain additional financing to support its operations. Sirona
Biochem does not assume any obligation to update any
forward-looking statements except as required by law.
For more information regarding this press release, contact:
Christopher HoptonCFOSirona Biochem Corp.
Phone: 1.604.282.6064Email: chopton@sironabiochem.com
Sirona Biochem (PK) (USOTC:SRBCF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sirona Biochem (PK) (USOTC:SRBCF)
Historical Stock Chart
From Jul 2023 to Jul 2024